ArticleThe oncologist2018
Prognostic Factors in Patients with Metastatic Breast Cancer with Bone-Only Metastases.
Article in The oncologist, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk factors and clinical significance of refractory pain in patients with bone metastases: a comprehensive meta-analysis.Frontiers in neurology · 2025Pooled it
- Evolving Paradigms in Cancer Pain Management: From Opioid-Centric Care to Multimodal and Personalized Strategies.Cancers · 2026Review
- Management of Bone-Only Progressive Disease in Metastatic Breast Cancer-A Retrospective Single-Center Analysis.Journal of clinical medicine · 2026Article
- Stereotactic body radiotherapy in patients with bone oligometastases from breast cancer - results from a European multicenter cohort study.Clinical and translational radiation oncology · 2026Article
- Article
- A Deep Learning Model for Comprehensive Automated Bone Lesion Detection and Classification on Staging Computed Tomography Scans.Academic radiology · 2025Article
- Factors Associating with Bone-Only Metastasis in Chinese Breast Cancer Patients in the Absence of Anti-Human Epidermal Growth Factor Receptor 2-Targeted Therapy.Oncology research and treatment · 2025Article
- Killing two birds with one stone: Siglec-15 targeting integrated bioactive glasses hydrogel for treatment of breast cancer bone metastasis.Materials today. Bio · 2024Article
- Survival outcomes for women with a solitary extracranial metastasis from breast cancer.Breast (Edinburgh, Scotland) · 2024Article
- Siglec-15/sialic acid axis as a central glyco-immune checkpoint in breast cancer bone metastasis.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- A Novel Algorithm for Evaluating Bone Metastatic Potential of Breast Cancer through Morphometry and Computational Mathematics.Diagnostics (Basel, Switzerland) · 2023Article
- The Role of Autophagy in Breast Cancer Metastasis.Biomedicines · 2023Review
- Article
- Machine learning in metastatic cancer research: Potentials, possibilities, and prospects.Computational and structural biotechnology journal · 2023Review
- Advancing Treatment of Bone Metastases through Novel Translational Approaches Targeting the Bone Microenvironment.Cancers · 2022Review
- Development and Validation of Prognostic Nomogram for Elderly Breast Cancer: A Large-Cohort Retrospective Study.International journal of general medicine · 2022Article
- Article
- Clinical Characteristics, Prognostic Factors and Treatment Outcomes of Patients with Bone-Only Metastatic Breast Cancer.Cancer management and research · 2022Article
- Breast cancer patients with isolated bone metastases and oligometastatic bone disease show different survival outcomes.Scientific reports · 2021Article
- Nomograms predict survival of patients with lymph node-positive, luminal a breast cancer.BMC cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPatients with metastatic breast cancer with bone-only metastases (BOM) are a unique patient population without consensus regarding high-risk characteristics, which we sought to establish.
methodsWe identified 1,445 patients with BOM followed for at least 6 months at MD Anderson Cancer Center from January 1, 1997, to December 31, 2015.
resultsSeventy-one percent (
conclusionOverall, several risk features for decreased OS were identified, including multiple bone metastases and both axial and appendicular skeleton involvement. Multiple bone metastases and lytic bone metastases were associated with increased pain. IMPLICATIONS FOR PRACTICE: Patients with metastatic breast cancer and bone-only metastases (BOM) represent a poorly characterized patient subset. The ability to identify unique patient characteristics at time of BOM diagnosis associated with increased morbidity or mortality would allow for recognition of patients who would benefit from more aggressive therapy. In this study, the largest sample of patients with BOM thus far reported is characterized, highlighting several higher-risk BOM groups, including those with multiple bone metastases and bone metastases in both the axial and appendicular skeleton at time of BOM diagnosis. In addition to tailoring current practices for these high-risk patients, ongoing studies of these patients are indicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.